Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -3.1% | 4.3% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 2.0 | 1.8 |
Pr/Book | 1.2 |
Latest | F'cast | |
---|---|---|
Revenue | 7.5% | 6.2% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-19 | 124.01 | (58.48) | (10.72)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-20 | 105.57 | (22.57) | (3.80)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-21 | 125.06 | (9.18) | (1.93)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-22 | 157.71 | (21.38) | (4.34)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-23 | 169.48 | (12.69) | (2.41)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Sep-24 | 179.90 | 7.70 | (0.10)p | n/a | n/a | n/a | n/a | 0.0% |
30-Sep-25 | 200.70 | 16.25 | 1.06p | 43.5 | n/a | n/a | n/a | 0.0% |
30-Sep-26 | 225.13 | 31.33 | 2.89p | 15.9 | 0.1 | +174% | n/a | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Form 8.5 (EPT/RI) - Benchmark Holdings Plc | 23-Apr-2024 | 10:44 | RNS |
Rule 2.9 Announcement | 23-Apr-2024 | 07:00 | RNS |
Form 8.5 (EPT/RI) - Benchmark Holdings plc | 22-Apr-2024 | 10:42 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 46.00p |
Change Today | 1.90p |
% Change | 4.31 % |
52 Week High | 47.30 |
52 Week Low | 34.00 |
Volume | 18,774 |
Shares Issued | 739.67m |
Market Cap | £340.25m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
No dividends found |
Time | Volume / Share Price |
16:35 | 7 @ 46.00p |
16:35 | 4 @ 46.00p |
16:35 | 3 @ 46.00p |
14:10 | 2,095 @ 46.00p |
14:10 | 11,000 @ 45.90p |
Chair | Peter George |
CFO | Septima Maguire |
CEO | Trond Williksen |
You are here: research